Association of OX40 expression with genetic landscape and clinical parameters
| Characteristic | Analyzed patients | P value two-sideda | Cox regression | Correlationb |
|---|---|---|---|---|
| PML/RARA t(15;17) | 96 | <0.05 | ||
| RUNX1/RUNX1T1 t(8;21) | 94 | n.s. | ||
| CBFB/MYH11 inv(16) | 93 | n.s. | ||
| Subtype of FLT3 mutation | ||||
| FLT3-ITD | 84 | <0.05 | ||
| FLT3-TKD | 83 | n.s. | ||
| NPM1 | 84 | n.s. | ||
| CEBPA | 55 | n.s. | ||
| MLL-PTD | 78 | n.s. | ||
| ELN | 90 | n.s. | ||
| ELN 2017 | 88 | n.s. | ||
| Survival | 105 | n.s. | ||
| CR | 63 | n.s. | ||
| Etiology | 108 | n.s. | ||
| pAML | 87 | |||
| sAML | 14 | |||
| tAML | 7 | |||
| Relapse | n.s. | |||
| FAB | 105 | n.s. | ||
| Age at diagnosis | 110 | n.s. | ||
| Sex | 110 | n.s. | ||
| PBB (%) | 109 | n.s. | ||
| WBC | 108 | n.s | ||
| Plt (G/L) | 108 | n.s. | ||
| HB (g/dL) | 108 | n.s. | ||
| CRP (mg/dL) | 108 | n.s. |
Abbreviations: ELN, European LeukemiaNet classification; ELN 2017, modified European LeukimiaNet classification; CR, complete remission; pAML, de novo AML; tAML, therapy-related AML; sAML, secondary AML evolving from MDS/MPS; FAB, French–American–British classification; PBB, peripheral blood blasts among nucleated cells; WBC, white blood count; Plt, platelets; HB, hemoglobin; CRP, C-reactive protein; n.s., not significant.
↵aAll P values are two-sided and were calculated either with Mann–Whitney or Kruskal–Wallis test or, for categorial variables, with the χ2 tests.
↵bCorrelation Spearman r.